MX2012013175A - Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan. - Google Patents
Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan.Info
- Publication number
- MX2012013175A MX2012013175A MX2012013175A MX2012013175A MX2012013175A MX 2012013175 A MX2012013175 A MX 2012013175A MX 2012013175 A MX2012013175 A MX 2012013175A MX 2012013175 A MX2012013175 A MX 2012013175A MX 2012013175 A MX2012013175 A MX 2012013175A
- Authority
- MX
- Mexico
- Prior art keywords
- hmg
- irbesartan
- coa reductase
- reductase inhibitor
- pharmaceutical formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steering Devices For Bicycles And Motorcycles (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se presenta una formulación farmacéutica en forma de comprimidos de dos fases que consiste en una primera fase que contiene irbesartan o sales aceptables desde el punto de vista farmacéutico de los anteriores y una segunda fase que contiene un inhibidor de HMG-CoA reductasa y un aditivo alcalino, que puede mejorar la velocidad de disolución y la estabilidad de irbesartan y un inhibidor de HMG-CoA reductasa para potenciar la biodisponibilidad del fármaco cuando se compara con formulaciones complejas convencionales y para minimizar la generación de los compuestos relacionados, de este modo usándose en forma efectiva como un agente terapéutico superior y estable para hipertensión y la hipercolesterolemia.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20100045636 | 2010-05-14 | ||
KR1020100053782A KR101248804B1 (ko) | 2010-05-14 | 2010-06-08 | HMG-CoA 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제 |
PCT/KR2011/003549 WO2011142621A2 (en) | 2010-05-14 | 2011-05-13 | Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012013175A true MX2012013175A (es) | 2013-01-17 |
MX342868B MX342868B (es) | 2016-10-17 |
Family
ID=45395310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012013175A MX342868B (es) | 2010-05-14 | 2011-05-13 | Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan. |
Country Status (36)
Country | Link |
---|---|
US (1) | US20130028974A1 (es) |
EP (1) | EP2568972B1 (es) |
JP (1) | JP5969466B2 (es) |
KR (2) | KR101248804B1 (es) |
CN (1) | CN103002883B (es) |
AR (1) | AR081032A1 (es) |
AU (2) | AU2011251085A1 (es) |
BR (1) | BR112012029064B8 (es) |
CA (1) | CA2798363C (es) |
CL (1) | CL2012003185A1 (es) |
CO (1) | CO6592025A2 (es) |
CR (1) | CR20120545A (es) |
DK (1) | DK2568972T3 (es) |
DO (1) | DOP2012000264A (es) |
EA (1) | EA023959B1 (es) |
EC (1) | ECSP12012224A (es) |
ES (1) | ES2645726T3 (es) |
GT (1) | GT201200309A (es) |
HK (1) | HK1181685A1 (es) |
HU (1) | HUE036638T2 (es) |
IL (1) | IL223012B (es) |
JO (1) | JO3409B1 (es) |
MA (1) | MA34313B1 (es) |
MX (1) | MX342868B (es) |
MY (1) | MY157307A (es) |
NI (1) | NI201200170A (es) |
NZ (1) | NZ604402A (es) |
PE (2) | PE20130204A1 (es) |
PL (1) | PL2568972T3 (es) |
PT (1) | PT2568972T (es) |
SG (1) | SG185778A1 (es) |
SI (1) | SI2568972T1 (es) |
TW (1) | TW201200166A (es) |
UA (1) | UA107967C2 (es) |
WO (1) | WO2011142621A2 (es) |
ZA (1) | ZA201209481B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103356500A (zh) * | 2012-03-30 | 2013-10-23 | 肖广常 | 一种瑞舒伐他汀钙非诺贝特酸胆碱盐择时渗透泵控释片及其制备方法 |
BR102012020648A2 (pt) * | 2012-08-17 | 2014-12-09 | Hypermarcas S A | Preparação farmacêutica oral sólida para a prevenção de doença cardio e cerebrovasculares e comprimido |
KR20140028971A (ko) * | 2012-08-31 | 2014-03-10 | 한미약품 주식회사 | 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제 |
KR20140030505A (ko) * | 2012-08-31 | 2014-03-12 | 한미약품 주식회사 | 이베살탄 및 HMG-CoA 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제 |
JP6068765B2 (ja) * | 2013-03-14 | 2017-01-25 | ボリュン ファーマスーティカル カンパニー リミテッド | 薬学的複合製剤 |
KR101597004B1 (ko) * | 2013-07-25 | 2016-02-23 | 씨제이헬스케어 주식회사 | 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제 |
KR101771766B1 (ko) * | 2013-12-30 | 2017-08-28 | 알보젠코리아 주식회사 | 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제 |
KR20150079373A (ko) * | 2013-12-30 | 2015-07-08 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 |
CN105769793A (zh) * | 2016-04-04 | 2016-07-20 | 孙爱华 | 一种辛伐他汀片剂及其制备方法 |
WO2020141825A1 (ko) * | 2018-12-31 | 2020-07-09 | 보령제약 주식회사 | 정제 및 이의 제조방법 |
KR102042626B1 (ko) * | 2019-06-26 | 2019-11-11 | 한미약품 주식회사 | 이베살탄 및 HMG-CoA 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제 |
WO2022260439A1 (ko) * | 2021-06-09 | 2022-12-15 | 주식회사 보령 | 약학적 복합 제제 및 제조 방법 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994348A (en) * | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
US6576256B2 (en) * | 2001-08-28 | 2003-06-10 | The Brigham And Women's Hospital, Inc. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
JP2003073270A (ja) * | 2001-08-30 | 2003-03-12 | Nisshin Seiyaku Kk | 安定性および溶出性の良好なプラバスタチンナトリウム錠 |
PT1854454E (pt) * | 2002-01-16 | 2014-01-09 | Boehringer Ingelheim Pharma | Método para a preparação de telmisartan amorfo |
WO2003105809A1 (en) * | 2002-06-17 | 2003-12-24 | Themis Laboratories Private Limited | Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them |
US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
US20060078615A1 (en) * | 2004-10-12 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Bilayer tablet of telmisartan and simvastatin |
KR20070104447A (ko) * | 2005-02-10 | 2007-10-25 | 라이프사이클 파마 에이/에스 | 페노피브레이트 및 HMG-CoA 리덕타제 억제제의 고정용량 배합물을 포함하는 안정한 약학 조성물 |
WO2007050485A2 (en) * | 2005-10-25 | 2007-05-03 | Merck & Co., Inc. | Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension |
WO2008010008A2 (en) * | 2006-07-17 | 2008-01-24 | Wockhardt Limited | Cardiovascular combinations using rennin-angiotensin inhibitors |
KR100985254B1 (ko) * | 2006-10-30 | 2010-10-04 | 한올바이오파마주식회사 | 방출성이 제어된 안지오텐신―Ⅱ―수용체 차단제와HMG―CoA 환원 효소 억제제의 복합 조성물 |
WO2008068217A2 (en) * | 2006-12-04 | 2008-06-12 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system |
KR101205633B1 (ko) * | 2008-04-29 | 2012-11-27 | 한올바이오파마주식회사 | 심혈관계 질환 치료용 약제학적 제제 |
WO2009134057A2 (ko) * | 2008-04-29 | 2009-11-05 | 한올제약주식회사 | 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제 |
KR20090114190A (ko) * | 2008-04-29 | 2009-11-03 | 한올제약주식회사 | 방출성이 제어된 HMG―CoA 환원 효소 억제제와안지오텐신―Ⅱ―수용체 차단제의 복합 조성물 |
CN101590231A (zh) * | 2008-05-29 | 2009-12-02 | 北京奥萨医药研究中心有限公司 | 血管紧张素ⅱ受体拮抗剂、他汀类降脂药和烟酸的药物组合物及其用途 |
CZ301299B6 (cs) * | 2008-11-24 | 2010-01-06 | Zentiva, A.S. | Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem |
-
2010
- 2010-06-08 KR KR1020100053782A patent/KR101248804B1/ko active IP Right Grant
-
2011
- 2011-05-10 AR ARP110101607A patent/AR081032A1/es unknown
- 2011-05-12 JO JOP/2011/0161A patent/JO3409B1/ar active
- 2011-05-13 NZ NZ604402A patent/NZ604402A/en not_active IP Right Cessation
- 2011-05-13 US US13/640,590 patent/US20130028974A1/en not_active Abandoned
- 2011-05-13 PT PT117808386T patent/PT2568972T/pt unknown
- 2011-05-13 PE PE2012002144A patent/PE20130204A1/es not_active Application Discontinuation
- 2011-05-13 MY MYPI2012004511A patent/MY157307A/en unknown
- 2011-05-13 HU HUE11780838A patent/HUE036638T2/hu unknown
- 2011-05-13 EA EA201291247A patent/EA023959B1/ru not_active IP Right Cessation
- 2011-05-13 CN CN201180023874.3A patent/CN103002883B/zh not_active Expired - Fee Related
- 2011-05-13 SG SG2012087227A patent/SG185778A1/en unknown
- 2011-05-13 DK DK11780838.6T patent/DK2568972T3/da active
- 2011-05-13 MA MA35460A patent/MA34313B1/fr unknown
- 2011-05-13 UA UAA201214276A patent/UA107967C2/ru unknown
- 2011-05-13 MX MX2012013175A patent/MX342868B/es active IP Right Grant
- 2011-05-13 PL PL11780838T patent/PL2568972T3/pl unknown
- 2011-05-13 BR BR112012029064A patent/BR112012029064B8/pt not_active IP Right Cessation
- 2011-05-13 CA CA2798363A patent/CA2798363C/en not_active Expired - Fee Related
- 2011-05-13 EP EP11780838.6A patent/EP2568972B1/en not_active Not-in-force
- 2011-05-13 SI SI201131287T patent/SI2568972T1/sl unknown
- 2011-05-13 WO PCT/KR2011/003549 patent/WO2011142621A2/en active Application Filing
- 2011-05-13 PE PE2015002384A patent/PE20151905A1/es not_active Application Discontinuation
- 2011-05-13 TW TW100116831A patent/TW201200166A/zh unknown
- 2011-05-13 AU AU2011251085A patent/AU2011251085A1/en not_active Abandoned
- 2011-05-13 JP JP2013510029A patent/JP5969466B2/ja not_active Expired - Fee Related
- 2011-05-13 ES ES11780838.6T patent/ES2645726T3/es active Active
-
2012
- 2012-10-04 DO DO2012000264A patent/DOP2012000264A/es unknown
- 2012-10-05 EC ECSP12012224 patent/ECSP12012224A/es unknown
- 2012-10-25 CR CR20120545A patent/CR20120545A/es unknown
- 2012-11-13 IL IL223012A patent/IL223012B/en not_active IP Right Cessation
- 2012-11-13 NI NI201200170A patent/NI201200170A/es unknown
- 2012-11-13 GT GT201200309A patent/GT201200309A/es unknown
- 2012-11-14 CL CL2012003185A patent/CL2012003185A1/es unknown
- 2012-12-10 CO CO12223131A patent/CO6592025A2/es unknown
- 2012-12-13 ZA ZA2012/09481A patent/ZA201209481B/en unknown
-
2013
- 2013-01-28 KR KR1020130009537A patent/KR20130024940A/ko not_active Application Discontinuation
- 2013-08-07 HK HK13109214.6A patent/HK1181685A1/zh not_active IP Right Cessation
-
2016
- 2016-06-03 AU AU2016203739A patent/AU2016203739B2/en not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JO3409B1 (ar) | صيغة صيدلانية في صورة أقراص ثنائية الطبقات تشتمل على مثبط لإنزيم HMG-CoA ريدكتاز وإربسارتان | |
MX346879B (es) | Formulaciones de ketorolaco listas para su uso. | |
MX2020011961A (es) | Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas. | |
NZ601595A (en) | Oral formulations and lipophilic salts of methylnaltrexone | |
MX2013014788A (es) | Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos. | |
MX2011013201A (es) | Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion. | |
NZ606123A (en) | Use of binders for manufacturing storage stable formulations | |
UA116334C2 (uk) | Тверді форми дозування бендамустину | |
NZ594214A (en) | Tablets comprising cobicistat, elvitegravir, emtricitabine and tenofovir disoproxil fumarate for combination therapy | |
TN2013000257A1 (en) | Immunosuppressant formulations | |
WO2009140341A3 (en) | Atorvastatin compositions | |
GEP20135859B (en) | Stable combined pharmaceutical composition | |
MX2012013872A (es) | Formas de dosificacion oral de bendamustina. | |
PH12015500395A1 (en) | Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor | |
WO2011108882A3 (ko) | 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물 | |
PH12015500394A1 (en) | Bilayered composite tablet formulation comprising atorvastatin, irbesartan and magnesium carbonate | |
UA110792C2 (uk) | Лікарська форма бендамустину для перорального застосування | |
TN2013000440A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
GR1007629B (el) | Φαρμακευτικο σκευασμα ελεγχομενης αποδεσμευσης ενος μη εργολινικου αγωνιστη της ντοπαμινης |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |